62,661 results match your criteria Lung Metastases


A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.

Lung Cancer 2020 Jun 24;147:26-29. Epub 2020 Jun 24.

Department of Oncology, The 904 Hospital of the Joint Logistic Support Force of the Chinese People's Liberation Army, Wuxi, Jiangsu, 214044, PR China. Electronic address:

The FAM179A gene has recently been screened as a new fusion partner fusing to the anaplastic lymphoma kinase gene (ALK) in plasma cell-free DNA (cfDNA) of patients with non-small-cell lung cancer (NSCLC). However, the response of patients with NSCLC harboring the FAM179A-ALK fusion to ALK inhibitors remains unknown. In this study we report a novel FAM179A-ALK rearrangement variant (F1, A19) identified by next-generation sequencing in an NSCLC patient with multiple brain metastases (M1c). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.06.026DOI Listing

Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.

J Thorac Oncol 2020 Jul 8. Epub 2020 Jul 8.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Introduction: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), efficiently penetrates the blood-brain barrier. Current study explored whether treatment with osimertinib leads to improved overall survival (OS) for EGFR-mutated NSCLC patients with leptomeningeal metastases (LM) compared with those not treated with osimertinib.

Methods: From October 2008 to October 2019, patients with EGFR-mutated NSCLC and cytologically confirmed LM were retrospectively analyzed for OS according to osimertinib treatment and T790M mutational status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.06.018DOI Listing

Individualized dosimetry in children and young adults with differentiated thyroid cancer undergoing iodine-131 therapy.

J Pediatr Endocrinol Metab 2020 Jul 13. Epub 2020 Jul 13.

Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Objectives The amount of Iodine-131 to treat young patients with differentiated thyroid cancer (DTC) has not been established so far. The purpose of this study was to perform and compare blood dosimetry by "Hanscheid's approach"and lesion dosimetry by "Maxon's approach". Methods Seventy-one DTC patients ≤21 years were given diagnostic activity of 74 MBq 131I followed by whole-body scan (WBS) at 2 h (pre-void), 24 h, 48 h, and ≥72 h. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpem-2020-0072DOI Listing

Solid Tumor Metastases to the Pancreas Diagnosed Using Fine-Needle Aspiration.

Am J Clin Pathol 2020 Jul 11. Epub 2020 Jul 11.

Department of Anatomical Pathology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston.

Objectives: Solid tumor metastases to the pancreas are rare, and only limited literature on the topic is available. In this retrospective study, we reviewed 107 cases of solid tumor metastases to the pancreas diagnosed by fine-needle aspiration (FNA) from 2005 to 2019.

Methods: Information including the patients' clinical histories, radiologic and pathologic findings, treatments, and follow-up were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqaa090DOI Listing

Metastases of soft tissue sarcoma to the liver: A Historical Cohort Study from a Hospital-based Cancer Registry.

Cancer Med 2020 Jul 10. Epub 2020 Jul 10.

Sarcoma Center, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.

Background: Hepatic metastasis of soft tissue sarcoma is rare compared to lung metastasis, and the literature is scarce. We examined the risk of hepatic metastasis according to the site of occurrence and histological type.

Methods: From a Hospital-based Cancer Registry, 658 patients registered between 2007 and 2017 with soft tissue sarcomas were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.3304DOI Listing

Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.

Ann Palliat Med 2020 Jun 30. Epub 2020 Jun 30.

Department of Geriatric Oncology, Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC), and it lacks standard treatment guidelines and is always accompanied by poor prognosis. We report a patient who was definitively diagnosed as LM from NSCLC with a targeted mutation of epidermal growth factor receptor (EGFR) via magnetic resonance imaging (MRI) and positive cerebrospinal fluid (CSF) cytology. Tyrosine kinase inhibitors (TKIs) were implemented but ineffective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-19-521DOI Listing

Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.

Ann Palliat Med 2020 Jun 29. Epub 2020 Jun 29.

Department of Thoracic Oncology, Cancer Center, West China Hospital, Medical School, Sichuan University, Chengdu, China.

Epidermal growth factor receptor (EGFR) L861Q mutation is a non-classical mutation, with a low incidence, poor response, and uncertain resistance mechanisms when treated by an EGFR tyrosine kinase inhibitor (EGFR-TKI). The liver is one of the most common distant organs to metastasize in nonsmall cell lung cancer (NSCLC), and achieving complete remission treatment for the liver is difficult. In this report, a patient was diagnosed with advanced lung adenocarcinoma harboring the EGFR L861Q mutation and responded well to afatinib for 16 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apm-19-482DOI Listing

Large surgically resected leiomyosarcoma of the liver: a case report.

Surg Case Rep 2020 Jul 9;6(1):168. Epub 2020 Jul 9.

Department of Surgery, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, Hiroshima 730-8619, Japan.

Background: Primary hepatic leiomyosarcoma (PHL) is an extremely rare type of tumor. We herein report a case of a large surgically resected leiomyosarcoma of the liver.

Case Presentation: A 69-year-old man with a feeling of epigastric compression was referred for examination of an abdominal mass. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-020-00934-6DOI Listing

Large-scale transcriptome analysis identified RNA methylation regulators as novel prognostic signatures for lung adenocarcinoma.

Ann Transl Med 2020 Jun;8(12):751

Department of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, China.

Background: The abnormal expression of genes is an essential factor affecting the prognosis of cancer. RNA modification is a way of regulating post-transcriptional levels, including mA, mC, mA RNA methylation. Studies have found that RNA methylation regulates tumorigenesis development and stem cell regeneration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm-20-3744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333141PMC

Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation.

Signal Transduct Target Ther 2020 Jul 10;5(1):117. Epub 2020 Jul 10.

Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, Shanghai, China.

Tumor cells transform into endothelial cells by epithelial-to-mesenchymal transition, which is characterized by vasculogenic mimicry (VM). VM not only accelerates tumor progression but also increases drug-induced resistance. However, very little is currently known about the molecular determinants that enable VM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41392-020-0167-1DOI Listing

A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Oncology (Williston Park) 2020 Jan;34(1):21-27

Thoracic Oncology Unit, Instituto Nacional de Cancerología, México City, México.

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood. Read More

View Article

Download full-text PDF

Source
January 2020

Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab.

Oncology (Williston Park) 2020 May;34(5):171-174

Associate Professor, Hematology and Medical Oncology Department. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Mexico City, Mexico.

A 56-year-old white man with a 74 pack-year smoking history presented with macroscopic hematuria and a significant weight loss of 45 pounds in 6 months. His clinical laboratory tests indicated iron defi ciency anemia and a computed tomography (CT) scan showed a left kidney tumor, mediastinal lymph nodes, and multiple lung metastases. A percutaneous CT-guided kidney biopsy revealed grade 3 clear cell renal carcinoma based on World Health Organization/International Society of Urologic Pathology classifi cation. Read More

View Article

Download full-text PDF

Source

The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study.

Croat Med J 2020 Jul;61(3):215-222

Ayat Faris, Department of Radiology and Physical Medicine, University of Granada, Avda. de la Ilustracion, 11, 18016- Granada, Spain,

Aim: To evaluate the efficacy of radiation therapy in alleviating pain and improving the quality of life (QoL) with validated questionnaires in patients with painful bone metastases (BoM).

Methods: This prospective, observational study recruited 167 patients with painful BoM who were treated with palliative radiotherapy (PRT) from February 2015 to February 2018. After the first clinical assessment, the patients filled out specific questionnaires and underwent a fast radiotherapy treatment within 48 hours. Read More

View Article

Download full-text PDF

Source

Diabetic mortality risk among cancer patients in the United State SEER population, 1975-2016.

Endocrine 2020 Jul 8. Epub 2020 Jul 8.

Department of Otolaryngology, Shanghai Key Clinical Disciplines of Otorhinolaryngology, Eye Ear Nose & Throat Hospital, Fudan University, Shanghai, PR China.

Background: The focus on diabetic mortality in cancer patients remains superficial. The objective of our study is to identify cancer patients with the highest risk of diabetic mortality compared with other cancer patients and the general US population.

Methods: The representative data of cancer patients dying from diabetes between 1975 and 2016 was retrieved from the Surveillance, Epidemiology, and End Results program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-020-02405-2DOI Listing

Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.

Neurooncol Adv 2020 Jul 10;2(Suppl 1):i75-i84. Epub 2019 Sep 10.

Division of Medical Oncology, Department of Medicine Washington University School of Medicine, St. Louis, Missouri.

Background: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with high metastatic rates and poor overall patient survival. There are currently no effective therapies, underscoring the pressing need to define the molecular etiologies that underlie MPNST progression. The aim of this study was to examine clonal progression and identify the molecular events critical for MPNST spread. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdz026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317063PMC

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa064. Epub 2020 May 28.

Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.

Background: Molecular and genetic alterations of non-small-cell lung cancer (NSCLC) now play a vital role in patient care of this neoplasm. The authors focused on the impact of epidermal growth factor receptor mutation (EGFR-mt) status on the survival of patients after brain metastases (BMs) from NSCLC. The purpose of the study was to understand the most desirable management of BMs from NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284117PMC

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa038. Epub 2020 Mar 16.

Clinical Cooperation Unit Neuro-Oncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: Salvage treatment for recurrent brain metastases (BM) of solid cancers is challenging due to the high symptomatic burden and the limited local treatment options.

Methods: Patients with recurrent BM with no option for further local therapies were retrospectively identified from BM databases. Bevacizumab-based treatment was initiated as a salvage treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212911PMC

Label-free multiphoton imaging allows brain tumor recognition based on texture analysis-a study of 382 tumor patients.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa035. Epub 2020 Mar 12.

Neurosurgery, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Background: Label-free multiphoton microscopy has been suggested for intraoperative recognition and delineation of brain tumors. For any future clinical application, appropriate approaches for image acquisition and analysis have to be developed. Moreover, an evaluation of the reliability of the approach, taking into account inter- and intrapatient variability, is needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212881PMC

Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa028. Epub 2020 Feb 28.

Department of Diagnostic Physics, Oslo University Hospital, Oslo, Norway.

Background: MRI may provide insights into longitudinal responses in the diffusivity and vascular function of the irradiated normal-appearing brain following stereotactic radiosurgery (SRS) of brain metastases.

Methods: Forty patients with brain metastases from non-small cell lung cancer ( = 26) and malignant melanoma ( = 14) received SRS (15-25 Gy). Longitudinal MRI was performed pre-SRS and at 3, 6, 9, 12, and 18 months post-SRS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212876PMC
February 2020

A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria.

Neurooncol Adv 2020 Jan-Dec;2(1):vdaa026. Epub 2020 Mar 10.

Department of Neurology, Haukeland University Hospital, Bergen, Norway.

Background: A major challenge in the follow-up of patients treated with stereotactic radiosurgery (SRS) for brain metastases (BM) is to distinguish pseudoprogression (PP) from tumor recurrence (TR). The aim of the study was to develop a clinical risk assessment score.

Methods: Follow-up images of 87 of 97 consecutive patients treated with SRS for 348 BM were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/noajnl/vdaa026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212847PMC

Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers.

J Thorac Dis 2020 May;12(5):1952-1959

Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Multiple synchronous lung tumors (MSLT), particularly within a single lobe, represent a diagnostic and treatment challenge. While histologic assessment was once the only method to possibly distinguish multiple primary lung cancers, there is a growing interest in identifying unique genomic features or mutations to best characterize these processes.

Methods: In order to differentiate multiple primary lung malignancies from intrapulmonary metastases in patients with MSLT, we performed whole exome sequencing (WES) on 10 tumor samples from 4 patients with MSLT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd-20-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330333PMC

Stereotactic irradiation of non-small cell lung cancer brain metastases: evaluation of local and cerebral control in a large series.

Sci Rep 2020 Jul 8;10(1):11201. Epub 2020 Jul 8.

Academic Department of Radiation Oncology, Centre Oscar Lambret, 59020, Lille Cedex, France.

Stereotactic radiotherapy (SRT) of brain metastases (BM) results are often reported in the heterogeneous primitive population. Here, we report our experience in consecutively treated patients who underwent SRT alone for BM from non-small cell lung cancer (NSCLC). This retrospective analysis included consecutive patients with no history of cerebral treatment who underwent Cyberknife™ SRT for BM from NSCLC in our institution from 2007 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-68209-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343798PMC

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis.

Sci Rep 2020 Jul 8;10(1):11203. Epub 2020 Jul 8.

Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Prior pooled analysis of eribulin studies (301 and 305) indicated eribulin prolonged overall survival (OS) in patients with locally advanced/metastatic breast cancer (MBC) regardless of visceral or nonvisceral disease. This hypothesis-generating post hoc analysis examined the efficacy of eribulin according to the location of metastatic sites at baseline in 1864 pretreated patients with locally advanced/MBC from studies 301 and 305. Analyses included OS, progression-free survival (PFS), and objective response rate; OS and PFS were also analyzed according to estrogen-receptor status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-66980-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343788PMC

Pazopanib-associated interstitial lung disease in a patient with renal cell carcinoma.

BMJ Case Rep 2020 Jul 8;13(7). Epub 2020 Jul 8.

Department of Diagnostic and Generalist Medicine, Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi, Japan

Pazopanib is a multi-targeted tyrosine kinase inhibitor, which is indicated for use in patients with advanced renal cell carcinoma or advanced soft-tissue sarcomas. Although rare, interstitial lung disease has been reported as among the adverse sequelae of pazopanib therapy. We report the case of a 75-year-old man who developed interstitial lung disease during treatment with pazopanib for renal cell carcinoma with multiple lung metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2020-235177DOI Listing

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis.

J Clin Med 2020 Jul 6;9(7). Epub 2020 Jul 6.

Department of Hepatobiliary, Pancreatic and Transplant Surgery, Freeman Hospital, Newcastle upon Tyne NE7 7DN, Tyne and Wear, UK.

Background: Neoadjuvant therapy (NAT) represents a paradigm shift in the management of patients with pancreatic ductal adenocarcinoma (PDAC) with perceived benefits including a higher R0 rate. However, it is unclear whether NAT affects the sites and patterns of recurrence after surgery. This review seeks to compare sites and patterns of recurrence after resection between patients undergoing upfront surgery (US) or after NAT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9072132DOI Listing

ALK-Brain Prognostic Index-Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases.

Cancers (Basel) 2020 Jul 6;12(7). Epub 2020 Jul 6.

Theme Cancer, Medical Unit Head & Neck, Lung and Skin Cancer, Karolinska University Hospital, 17176 Stockholm, Sweden.

Background: Disease-specific Graded Prognostic Assessment (DS-GPA) is the most validated prognostic tool for patients with brain metastasized lung cancer. The Lung-molGPA scoring system was recently introduced for oncogenic-driven brain metastasized lung cancer, but has not yet been validated in cohorts including only ALK-translocated tumors.

Methods: We designed a retrospective cohort study consisting of 44 patients with brain metastasized ALK-positive, non-small cell lung cancer (NSCLC) who were treated between January 2009 and November 2019 at Karolinska University Hospital in Stockholm, Sweden. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071804DOI Listing

Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).

Oncology 2020 Jul 8:1-8. Epub 2020 Jul 8.

National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Background: Molecular targeted drugs having angiogenesis-inhibiting properties allow the induction of necrosis inside tumors. We retrospectively investigated the relationship between changes on imaging associated with regorafenib (REGO) and treatment outcomes using real-world data.

Patients And Methods: The eligibility criteria included an ECOG PS of 0-1, a starting dose of 120 or 160 mg/day of REGO, and a duration of treatment of at least 35 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507814DOI Listing

Clinical Significance of Station 3A Lymph Node Dissection in Patients with Right-Side Non-Small-Cell Lung Cancer: A Retrospective Propensity-Matched Analysis.

Ann Surg Oncol 2020 Jul 7. Epub 2020 Jul 7.

Department of Thoracic Surgery, West China Hospital, Chengdu, Sichuan, China.

Purpose: To investigate the prognostic impact of station 3A lymph node (LN) dissection in patients with right-side non-small-cell lung cancer (NSCLC).

Patients And Methods: We retrospectively reviewed data of 1906 patients with primary right-side NSCLC who underwent lobectomy between January 2005 and December 2017 (570 patients underwent station 3A LN dissection and 1336 patients did not). Propensity score matching was conducted to minimize the effects of potential confounding factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08786-yDOI Listing

Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer.

Heliyon 2020 Jun 29;6(6):e04319. Epub 2020 Jun 29.

Department of Internal Medicine, Section of Medical Oncology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, NH, 03765, USA.

Background: There are limited data and conflicting guideline recommendations regarding the role of neuroimaging in the pretreatment evaluation of non-small cell lung cancer (NSCLC).

Methods: We performed a retrospective, pragmatic cohort study of patients with NSCLC diagnosed between January 1 and December 31, 2015. Eligible patients were identified from an institutional tumor registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.heliyon.2020.e04319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330068PMC

Metastases to the Kidney: A Case Report and Review of the Literature.

Curr Health Sci J 2020 Jan-Mar;46(1):80-89. Epub 2020 Mar 31.

2 Department, Imaging discipline, University of Medicine and Pharmacy of Craiova, Romania.

Renal metastases are uncommon in clinical practice, even as autopsy reports much frequent cases în disseminated tumors. Usually multiple and bilateral, they can determine many problems of differential diagnosis in case of solitary renal mass, when a primary kidney neoplasm must be excluded. Main sources are represented by the tumors of the lung, breast, digestive tract, melanomas and lymphomas, but rare cases with other etiology have been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12865/CHSJ.46.01.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323720PMC

A paravertebral approach for CT-guided percutaneous biopsy of presumably inaccessible, posterior and centrally located pulmonary nodules.

Radiol Case Rep 2020 Aug 27;15(8):1377-1380. Epub 2020 Jun 27.

Radiology department, Hôpital Cochin, APHP.Centre, Université de Paris, 27 rue du Faubourg Saint Jacques, 75014 Paris, France.

To present 3 cases were a paravertebral approach had to be used for the biopsy of posterior and centrally located pulmonary nodules. Three patients underwent percutaneous CT-guided transthoracic biopsy of pulmonary nodules that were initially thought to be inaccessible because of their central, posterior location by a paravertebral approach. The first 2 patients had a history of extra thoracic malignancy and the third patient presented with a bone metastasis and an isolated pulmonary nodule in the right lower lobe, corresponding to potential stage IV lung cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radcr.2020.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327127PMC

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.

Front Immunol 2020 19;11:1127. Epub 2020 Jun 19.

Department of Abdominal Oncology, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. We reported a case of a metastatic PDAC patient who had a long-term partial response and good tolerance to the combined approach of toripalimab (a novel PD-1 inhibitor) and gemcitabine plus nab-paclitaxel (GA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.01127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318868PMC

[Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation].

Rev Mal Respir 2020 Jul 4. Epub 2020 Jul 4.

Service de pneumologie, CH de Montauban, Montauban, France.

Introduction: Immunotherapy is now a standard of care in oncology. There is a need to improve our knowledge about immune-related adverse events, especially infectious diseases.

Case Report: We describe the case of a 49-year old male who received anti-PD1 therapy, to treat metastatic melanoma with pulmonary metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmr.2020.06.003DOI Listing

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.

Ann Oncol 2020 Jul 4. Epub 2020 Jul 4.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

Background: Up to 40% of patients with non-small cell lung cancer (NSCLC) and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) present with disease progression in the central nerve system (CNS), either as brain metastases (BM) or leptomeningeal metastases (LM). Osimertinib (80mg), a third generation, irreversible, oral EGFR TKI, has shown efficacy in active CNS metastases. However, efficacy of 160mg osimertinib in BM or LM is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.017DOI Listing

Survival outcome of palliative primary tumor resection for colorectal cancer patients with synchronous liver and/or lung metastases: A retrospective cohort study in the SEER database by propensity score matching analysis.

Int J Surg 2020 Jul 4. Epub 2020 Jul 4.

Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, 510080, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510515, China; Medical College of Shantou University, Shantou, Guangdong, 515000, China; School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China. Electronic address:

Background: There is a great matter of controversies whether some of these synchronous metastatic colorectal cancer patients can benefit from palliative primary tumor resection (pPTR) and there is still no reported randomized control trial to address this issue.

Methods: Patients with microscopically proven metastatic colorectal cancer were identified within the SEER database (2010 to 2016). Patients were propensity matched 1:1 into pPTR and non-surgery groups and among the matched cohort, the univariable and multivariable Cox proportional hazards regression models were performed to identify predictors of survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijsu.2020.06.024DOI Listing

Origin of circulating free DNA in patients with lung cancer.

PLoS One 2020 7;15(7):e0235611. Epub 2020 Jul 7.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Liquid biopsy has become widely applied in clinical medicine along with the progress in innovative technologies, such as next generation sequencing, but the origin of circulating tumor DNA (ctDNA) has not yet been precisely established. We reported bimodal peaks of long fragment circulating free DNA (cfDNA) of 5 kb and short fragment cfDNA of 170 bp in patients with advanced lung cancer, and both contained ctDNA. In this paper, we demonstrate that the total amount of cfDNA is higher when patients with lung cancer have extrathoracic metastases, and the amount of long fragment cfDNA is significantly higher in those patients. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235611PLOS

Incidence, prevalence, and outcomes of systemic malignancy with bone metastases.

J Orthop Surg (Hong Kong) 2020 Jan-Apr;28(2):2309499020915989

Department of Orthopedic Surgery, Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China.

Purpose: Evidence on the incidence, prevalence, and outcomes of bone metastases among patients with systemic malignancy is limited. This study aimed to evaluate it using the Surveillance, Epidemiology, and End Results (SEER) database.

Methods: We collected patients diagnosed with solid malignant tumors deriving outside of the bone, hematologic malignancies, Kaposi sarcoma, lymphoma, and myeloma from the SEER database (from 2010 to 2013). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2309499020915989DOI Listing

A forehead hematoma as the initial clinical sign of lung cancer.

Arch Craniofac Surg 2020 Jun 29;21(3):198-201. Epub 2020 Jun 29.

Department of Plastic and Reconstructive Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.

Primary lung cancer commonly metastasizes to the brain, bones, liver, and adrenal glands. In some cases, bone metastasis serves as the first presenting sign of lung cancer with bone pain and headache, but it is not common. The incidence of skull metastasis in lung squamous cell carcinoma (SCC) is low, and there have been only a few cases of skull metastases serving as the first sign of malignancy with skull mass and epidural bleeding; however, no similar cases have been reported regarding that of hematoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7181/acfs.2020.00129DOI Listing

Low Galectin-3 Expression Level in Primary Tumors Is Associated with Metastasis in T1 Lung Adenocarcinoma.

J Clin Med 2020 Jun 25;9(6). Epub 2020 Jun 25.

Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.

Background And Objective: Although nodal and distant metastasis is rare in T1 lung adenocarcinoma, it is related to poor clinical prognosis. Association between galectin-3 (Gal-3) expression level, and clinical outcome of T1 lung adenocarcinoma has not been clarified.

Methods: From January 2009 to December 2014, 74 patients with surgically resected T1 lung adenocarcinoma were enrolled in this retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9061990DOI Listing

Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.

Medicine (Baltimore) 2020 Jul;99(27):e21004

Division of Medical Oncology A, Policlinico Umberto I, Sapienza University of Rome, Rome.

Rationale: Choroidal metastasis is a rare metastatic location although the most common intraocular neoplasm. In general, choroidal metastases respond favorably to systemic therapy targeted toward the primary neoplasm. In patients with choroidal metastasis of ALK rearranged non small cell lung cancer (NSCLC), targeted therapy using Alk inhibitors gradually replaced radiotherapy as the best treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000021004DOI Listing

Ultrasound-guided superior laryngeal nerve block assists in anesthesia for bronchoscopic surgical procedure: A case report of anesthesia for rigid bronchoscopy.

Medicine (Baltimore) 2020 Jul;99(27):e20916

Department of Anesthesiology.

Introduction: Evolving techniques in the field of therapeutic bronchoscopy have led to the return of rigid bronchoscopy in the treatment of complex central airway disease. Rigid bronchoscopy is typically performed under general anesthesia because of the strong stimulation caused by metal instruments. Anesthesia for rigid bronchoscopy is challenging to administer because anesthesiologists and interventionists share the same working channel: the airway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020916DOI Listing

Hand metastasis in a patient with cervical cancer: A case report.

Medicine (Baltimore) 2020 Jul;99(27):e20897

Department of Clinical Research, National Cancer Institute.

Introduction: Acrometastasis is infrequent and generally indicates a wider spread of metastasis with poor prognosis. The diagnosis is challenging, as it might mimic an infectious, inflammatory, or metabolic disease. Acrometastasis are most commonly found in patients with lung, gastrointestinal, kidney, and breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020897DOI Listing

[Chest Wall Reconstruction Using Polypropylene Mesh: a Single-Center 8-Year Analysis].

Zentralbl Chir 2020 Jul 6. Epub 2020 Jul 6.

Lungenklinik, Lehrstuhl für Thoraxchirurgie, Universität Witten/Herdecke, Kliniken der Stadt Köln gGmbH, Deutschland.

Background: Chest wall resection for malignant tumours is usually combined with reconstruction of the bony defect. We analysed our single centre, 8-year, experience using polypropylene mesh for chest wall reconstruction. The goal of our retrospective study was to identify material-related complications and to compare them with the existing literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1180-9621DOI Listing

Fucosyltransferase 4 shapes oncogenic glycoproteome to drive metastasis of lung adenocarcinoma.

EBioMedicine 2020 Jul 3;57:102846. Epub 2020 Jul 3.

Department of Internal Medicine, National Taiwan University Hospital, No. 7, Zhongshan S Rd, Zhongzheng District, Taipei 10002, Taiwan; Graduate Institute of Toxicology, College of Medicine, National Taiwan University, No. 1, Jen Ai Rd, Section 1, Zhongzheng District, Taipei 10051, Taiwan. Electronic address:

Background: Aberrant fucosylation plays a critical role in lung cancer progression. Nevertheless, the key fucosyltransferase with prognostic significance in lung cancer patients, the enzyme's intracellular targets, and complex molecular mechanisms underlying lung cancer metastasis remain incompletely understood.

Methods: We performed a large-scale transcriptome-clinical correlation to identify major fucosyltransferases with significant prognostic values. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2020.102846DOI Listing

Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands.

Eur J Cancer 2020 Jul 3;136:35-42. Epub 2020 Jul 3.

Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Background: Distant metastases in adenoid cystic carcinoma (ACC) are common. There is no consensus on the management of metastatic disease because no therapeutic approach has demonstrated improvement in overall survival (OS) and because of prolonged life expectancy. The aim of this study is to build and validate a prognostic nomogram for metastatic ACC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.013DOI Listing

Incidence of hippocampal metastases in non-small-cell lung cancer.

J Med Imaging Radiat Oncol 2020 Jul 5. Epub 2020 Jul 5.

Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.

Objectives: Patients with locally advanced non-small-cell lung cancer (LA-NSCLC) develop brain metastases in 25-50% of cases during the course of their disease. Data on the incidence of metastases occurring in the hippocampus/perihippocampal zones are limited. This is important when considering hippocampal-sparing brain radiation (HS-BR), a method that could potentially reduce the neurocognitive impact of such treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1754-9485.13079DOI Listing

Case of a Long-Time Survivor with Recurrent Multiple Brain Metastases from Lung Cancer: Terminal Stage Cancer or Chronic Disease.

Authors:
Ming Pan

Cureus 2020 May 31;12(5):e8378. Epub 2020 May 31.

Radiation Oncology, Windsor Regional Hospital Cancer Program, Windsor, CAN.

Lung cancer with brain metastasis has a poor prognosis and has always been treated with palliative intent in the past. We report a case of good response to two courses of whole brain irradiation (WBI) and one course of hypofractionated stereotactic radiotherapy (HSRT) over a nine-year period, with no significant neurotoxicity. We present the case of a 43-year-old non-smoker female with biopsy-proven adenocarcinoma of right lower lobe lung, stage T1N2M0, positive for anaplastic lymphoma kinase (ALK). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.8378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328698PMC

Interval between planning and frameless stereotactic radiosurgery for brain metastases: are our margins still accurate?

Neurooncol Pract 2020 Mar 1;7(2):211-217. Epub 2019 Oct 1.

CHU-Bordeaux, Radiotherapy Department, France.

Background: Advances in intracranial stereotactic radiosurgery (SRS) have led to dramatically reduced planning target volume (PTV) margins. However, tumor growth between planning and treatment may lead to treatment failure. Our purpose was to assess the kinetics of tumor growth before SRS for brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/nop/npz048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318853PMC